Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Influx HealthtechNSE:INFLUX +1.75%21 Return-on-Tangible-Equity is 22.05% as of Mar. 2026, which is 66% below its 10-year median of 64.75. GuruFocus rates NSE:INFLUX with a GF Score™ of 21/100. The stock has 4 warning signs investors should review. Among 900 Drug Manufacturers companies, Influx Healthtech ranks better than 85.22% on this metric.
Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. Influx Healthtech's annualized net income for the quarter that ended in Mar. 2026 was ₹211 Mil. Influx Healthtech's average shareholder tangible equity for the quarter that ended in Mar. 2026 was ₹955 Mil. Therefore, Influx Healthtech's annualized Return-on-Tangible-Equity for the quarter that ended in Mar. 2026 was 22.05%.
The historical rank and industry rank for Influx Healthtech's Return-on-Tangible-Equity or its related term are showing as below:
NSE:INFLUX'
s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: 27.14 Med: 64.75 Max: 99.54
Current: 27.14
During the past 5 years, Influx Healthtech's highest Return-on-Tangible-Equity was 99.54%. The lowest was 27.14%. And the median was 64.75%.
NSE:INFLUX's Return-on-Tangible-Equity is ranked better than 85.22% of 900
companies
in the Drug Manufacturers industry
Industry Median: 7.895
vs NSE:INFLUX: 27.14
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
Influx Healthtech Return-on-Tangible-Equity Related Terms
Influx Healthtech Return-on-Tangible-Equity Historical Data
* Premium members only.
The historical data trend for Influx Healthtech's Return-on-Tangible-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NSE:INFLUX vs ZTS: Return-on-Tangible-Equity Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Influx Healthtech's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Influx Healthtech Return-on-Tangible-Equity vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Influx Healthtech's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where Influx Healthtech's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is two times the semi-annual (Mar. 2026) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of 22.05% mean?
Influx Healthtech (NSE:INFLUX) has a Return-on-Tangible-Equity of 22.05% as of Mar. 2026. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Influx Healthtech and its competitors. This is 66% below median its historical median of 64.75. Over the past decade, Influx Healthtech's Return-on-Tangible-Equity has ranged from 27.14 to 99.54. According to the industry distribution chart, Influx Healthtech ranks #133 out of 900 companies in the Drug Manufacturers industry, placing it in the top 14.8%.
Is Influx Healthtech's Return-on-Tangible-Equity too high?
Influx Healthtech's current Return-on-Tangible-Equity of 22.05% is 66% below median its 10-year median of 64.75. Over the past 10 years, this metric has ranged from a low of 27.14 to a high of 99.54. The Drug Manufacturers industry median Return-on-Tangible-Equity is 7.90. Influx Healthtech's value of 22.05% is 179.3% above this industry median. Based on the distribution chart, Influx Healthtech ranks #133 out of 900 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Influx Healthtech has a GF Score™ of 21/100, reflecting its overall financial health beyond just this single metric.
How does Influx Healthtech's Return-on-Tangible-Equity compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Influx Healthtech ranks #133 out of 900 companies for Return-on-Tangible-Equity. This places Influx Healthtech in the top 15% of its industry — outperforming the majority of peers. The industry median Return-on-Tangible-Equity is 7.90. Influx Healthtech's value of 22.05% is 179.3% above this benchmark. Historically, Influx Healthtech's own Return-on-Tangible-Equity has ranged from 27.14 to 99.54 over the past decade. While the company's 10-year median is 64.75 vs. the industry median of 7.90, Influx Healthtech has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Drug Manufacturers company?
The median Return-on-Tangible-Equity among Drug Manufacturers companies is 7.90, based on 900 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Equity significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Influx Healthtech's current Return-on-Tangible-Equity of 22.05% is 179.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Influx Healthtech and its competitors. For the Drug Manufacturers industry, the median Return-on-Tangible-Equity is 7.90 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Influx Healthtech's current Return-on-Tangible-Equity is 22.05%, which is 66% below median its own 10-year median of 64.75. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Influx Healthtech stock overvalued right now?
Influx Healthtech (NSE:INFLUX) has a current Return-on-Tangible-Equity of 22.05%. The current Return-on-Tangible-Equity is 22.05%, which is 66% below median its 10-year median of 64.75 and 179.3% above the Drug Manufacturers industry median of 7.90. Influx Healthtech's overall GF Score™ is 21/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For Influx Healthtech (NSE:INFLUX), the current Return-on-Tangible-Equity is 22.05% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Influx Healthtech Ltd is a Mumbai-based, healthcare-focused company specialising in contract manufacturing. The company operates manufacturing facilities located in Thane. Its expertise spans the production of Dietary and Nutritional Supplements, Cosmetics, Ayurvedic/Herbal Products, Veterinary Feed Supplements, Homecare Products, Active Pharmaceutical Ingredients (APIs), and finished dosage forms, including tablets, capsules, and injectables. The company generates the majority of its revenue from sale of products.
21GF Score
Get the complete analysis for NSE:INFLUX
Return-on-Tangible-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:INFLUX has been successfully added to your 
